Mixed trend on the daily chart: below its 200-day average, above its 50-day · 50-day below the 200-day · SuperTrend up since Oct 6 · above the Ichimoku cloud · RSI 58 · MACD above its signal
None of the 29 investors followed here reported a position in MDNA.TO in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a MDNA.TO trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
No insider transactions reported for MDNA.TO.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -4.3 | 2.3 | -28.9 | -7.8 | -28.0 | -7.1 | -8.9 | 30.6 | -18.1 | 14.3 | −52.2% | ||
| 2025 | -20.0 | -21.2 | -5.8 | 18.4 | -18.1 | -10.5 | -1.2 | 29.8 | -10.1 | 51.0 | 8.1 | -42.5 | −44.2% |
| 2024 | 1.2 | 163.5 | 66.1 | 24.7 | 22.8 | -29.1 | 5.4 | 15.5 | -23.2 | 24.9 | -27.1 | -4.1 | +292.9% |
| 2023 | 50.0 | -14.6 | 7.3 | 2.3 | -10.0 | -21.0 | -3.1 | -17.7 | -21.6 | -36.3 | 92.2 | -14.3 | −34.4% |
| 2022 | -3.8 | -7.9 | -11.3 | -13.9 | -9.2 | 14.7 | 35.1 | -39.0 | -7.4 | -13.3 | -28.6 | -8.6 | −69.5% |
| 2021 | -15.9 | 0.7 | 1.4 | -12.9 | 4.5 | -19.6 | -15.8 | -3.5 | 14.1 | -19.6 | -14.7 | -11.8 | −64.7% |
| 2020 | 0.0 | -6.2 | 12.9 | -10.0 | 116.0 | -30.4 | 1.8 | 17.3 | -6.0 | -10.1 | 0.2 | 20.7 | +75.0% |
| 2019 | 27.1 | -5.6 | -9.5 | -2.6 | 13.5 | 79.8 | -24.5 | -7.0 | 32.1 | -7.1 | 3.8 | 151.9 | +385.7% |
| 2018 | 0.0 | 15.0 | -13.0 | -17.5 | -3.6 | -7.5 | -5.4 | 15.1 | -18.8 | 23.1 | -24.4 | -42.1 | −65.0% |
| 2017 | -10.0 | -18.5 | -11.4 | -12.8 | -11.8 | 43.3 | 31.2 | -19.9 | -11.5 | −33.3% |
Buy / hold / sell counts
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.
No recent headlines.